Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.08.23	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (RSS)
30.08.23	Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences (Businesswire)
30.08.23	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (Businesswire)
24.08.23	European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV (Businesswire)
21.08.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age (Businesswire)
14.08.23	Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma (Businesswire)
01.08.23	Pfizer Reports Second-Quarter 2023 Results (Businesswire)
27.07.23	Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy (Businesswire)
21.07.23	Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility (Businesswire)
19.07.23	Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate (Businesswire)
14.07.23	There is no Alternative-Investmentansatz: Das steckt hinter der TINA-Strategie (finanzen.ch) Das griffige Kürzel TINA - There is no Alternative - genoss in den letzten Jahren in Börsenkreisen Hochkonjunktur. Experten erklärten mit TINA die Börsen-Hausse, Vermögensverwalter rieten mit TINA zum Aktienkauf und junge Trader riefen mit TINA zum Kauf von Meme-Aktien auf. Doch was genau steckt hinter diesen ominösen Buchstaben? Und welche Risiken bestehen bei dem Ansatz?» mehr
28.06.23	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (Businesswire)
27.06.23	FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec (Businesswire)
26.06.23	Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus (Businesswire)
23.06.23	FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata (Businesswire)
23.06.23	Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
23.06.23	Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine (RSS)
22.06.23	Pfizer Declares Third-Quarter 2023 Dividend (Businesswire)
21.06.23	Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval (Businesswire)
20.06.23	Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts (Businesswire)
08.06.23	Die Expertenmeinungen zur Pfizer-Aktie im Mai 2023 (finanzen.net) Experten haben im abgelaufenen Monat ihre Einschätzung zur Pfizer-Aktie veröffentlicht.» mehr
06.06.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.23	Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
31.05.23	U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults (Businesswire)
30.05.23	Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (Businesswire)
26.05.23	Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission (RSS)
25.05.23	Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting (Businesswire)
25.05.23	Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 (Businesswire)
18.05.23	FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization (Businesswire)
17.05.23	Pfizer Prices $31,000,000,000 Debt Offering (Businesswire)
15.05.23	Pfizer Announces Proposed Notes Offering (Businesswire)
02.05.23	Pfizer Reports First-Quarter 2023 Results (Businesswire)
27.04.23	U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children (Businesswire)
26.04.23	Pfizer Declares Second-Quarter 2023 Dividend (Businesswire)
13.04.23	Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 (Businesswire)
04.04.23	FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI (Businesswire)
21.03.23	Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts (Businesswire)
16.03.23	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ (Businesswire)
14.03.23	Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
13.03.23	Pfizer Invests $43 Billion to Battle Cancer (Businesswire)
10.03.23	Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval (Businesswire)
01.03.23	Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years (RSS)
28.02.23	Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults (Businesswire)
27.02.23	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
22.02.23	Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance (Businesswire)
21.02.23	U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review (Businesswire)
16.02.23	Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study (Businesswire)
16.02.23	Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults (Businesswire)
10.02.23	FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) (Businesswire)
10.02.23	Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program (RSS)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.90	4.77 %	K V
Swiss Life Hldg	693.00	0.84 %	K V
Zurich Insur Gr	552.40	0.84 %	K V
Kuehne+Nagel Int	206.50	0.73 %	K V
Sonova Hldg	294.20	0.65 %	K V
Sika	227.60	-1.30 %	K V
Part Grp Hldg	1’264.50	-1.56 %	K V
Geberit	538.20	-1.61 %	K V
Alcon	75.22	-1.75 %	K V
Lonza Grp	533.80	-2.63 %	K V

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten